Since it was reported that Th17 cells are induced by TGF-β, IL-1, IL-6, IL-21 or IL-23, antibodies targeting IL-6 or IL-23 have been considered strong candidates for the development as treatments for autoimmune diseases, including IBD and rheumatoid arthritis (1,20). Here, TGFB1 is linked to inflammatory bowel disease.